Pharma Not-For-Profit Projects Can Only Improve Reputation

Increased Focus on Planet, Not Just Pills

08 Apr 2021

Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.

Sanofi CEO Paul Hudson taking social responsibility seriously • Source: Sanofi

Big pharma’s reputation with the public seems to have risen given its leading role in tackling the pandemic but beyond COVID-19, drugmakers will be hoping their efforts in tackling pressing issues such as healthcare inequalities and climate change can build on that goodwill.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Galapagos Chief Exec Stoffels Leaving, While Firm Names Spinout’s CEO

22 Apr 2025

• By Mandy Jackson

Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.

Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

22 Apr 2025

• By Vibha Ravi

Enzene's CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier's India visit, he also talks about front-loading capacity at Enzene's US plant and a change in its biosimilars strategy

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

21 Apr 2025

• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

17 Apr 2025

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.